Multikinase Inhibitors in Refractory Metastatic Colorectal Cancer: An Optimal Sequence?

Abstract: Despite major advances in management strategies, metastatic colorectal cancer remains an important clinical challenge because most patients experience progression after standard first- and second-line treatments. […]

The Clinical Applications of Next-Generation Sequencing and ctDNA/cfDNA in Lymphoma

Abstract: Next-generation sequencing (NGS) technology plays a pivotal role in understanding the molecular landscape in oncology by providing a comprehensive analysis of genomic mutations. The detection […]

The Evolution of Treatment for Uveal Melanoma

H&O  What distinguishes uveal melanoma from cutaneous melanoma biologically? SK  Although these 2 tumors are both melanomas—they have the same cell of origin, the melanocyte—they are […]

Use of Menin Inhibitors for Acute Leukemia

H&O  What is the mechanism of action of menin inhibitors? GI  Menin inhibitors are a new class of drugs for patients with acute leukemia that work […]

Adoptive Cell Therapy for Ovarian Cancer

H&O  What are the shortcomings of existing therapies for ovarian cancer? KO  Standard therapy in patients with newly diagnosed ovarian cancer consists of neoadjuvant chemotherapy followed […]

Letter From the Editor: Ambassadors for Hope

Oncology is a hard field to be in at any time of the year, but especially now. It’s winter, the holidays are over, and the days […]

Fixed-Duration vs Continuous Treatment for Chronic Lymphocytic Leukemia in the CLL17 Trial

H&O  What was the impetus for the CLL17 trial? OA  Over the past 5 to 10 years, we have seen the evolution of 2 treatment paradigms […]

Highlights in Chronic Lymphocytic Leukemia From the 67th ASH Annual Meeting and Exposition

A Review of Selected Presentations From ASH 2025  •  December 6-9, 2025  •  Orlando, Florida Post Hoc Safety Analysis and Exploratory Analysis of Impact of Prognostic […]

View More Issues